Benjamin Bakall
Retina Specialist · Phoenix, AZNPI 1700085222
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (39.7%), ownership interests and consulting fees — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 64.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $58,538 and has fallen 72.4% since, to $16,181 in 2025.
Across 350 payments — averaging $390.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$87K
- Regeneron$11K
- Genentech, Inc.$9K
- F. Hoffmann-la Roche AG$6K
- AbbVie$6K
- Rhythm Pharmaceuticals, Inc.$4K
- plus $14K from 19 others
Across 120 payments — averaging $3365.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$127K
- Biogen$81K
- Genentech, Inc.$61K
- Hoffmann-la Roche Limited$43K
- Sanofi$30K
- Regeneron$24K
- plus $38K from 3 others
What the payments were for
- Consulting fees$32,19024%
- Speaking & faculty fees$1,7571%
- Travel & lodging$2,8472%
- Food & beverage$12,7629%
- Education$610%
- Ownership interest$32,83024%
- Other$54,22740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 14 | $87,499 |
| Regeneron | 18 | $11,177 |
| Genentech, Inc. | 7 | $8,580 |
| F. Hoffmann-la Roche AG | 4 | $5,911 |
| AbbVie(2 entities) | 65 | $5,512 |
| Rhythm Pharmaceuticals, Inc. | 4 | $3,766 |
| Genentech USA, Inc. | 22 | $3,551 |
| Alimera Sciences, Inc. | 19 | $2,829 |
| Regeneron Healthcare Solutions, Inc. | 90 | $2,599 |
| Apellis Pharmaceuticals, Inc. | 13 | $1,625 |
| Astellas Pharma US Inc | 17 | $665 |
| Bausch & Lomb Americas Inc. | 16 | $612 |
| Eyepoint US, Inc. | 20 | $574 |
| Notal Vision, Inc. | 2 | $507 |
| Novartis | 13 | $499 |
| Alcon Research LLC | 1 | $182 |
| Harrow Eye, LLC | 4 | $124 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $93 |
| Astellas Pharma Global Development | 1 | $83 |
| Glaukos Corporation | 1 | $73 |
| ANI Pharmaceuticals, Inc. | 4 | $70 |
| Alcon | 3 | $60 |
| Coherus Oncology, Inc. | 1 | $29 |
| Spark Therapeutics, Inc. | 1 | $28 |
| Travere Therapeutics, Inc. | 8 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$136,673 in reported general payments places this provider in the 85th percentile of 30 retina specialist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 147 | $8,591 |
| Difluprednate | 34 | $3,584 |
| Latanoprost | 236 | $3,205 |
| Brimonidine Tartrate | 63 | $1,978 |
| Dorzolamide Hcl | 62 | $1,394 |
| TafluprostTafluprost/Pf | 11 | $1,102 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 101 | $1,002 |
| Ofloxacin | 79 | $987 |
| Timolol Maleate | 70 | $700 |
| Ketorolac Tromethamine | 25 | $556 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 24 | $351 |
| Prednisone | 18 | $105 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Phoenix
- Jordan GraffPhoenix$483K
- Rahul ReddyPhoenix$333K
- Henry KwongPhoenix$147K
- Jaime GaitanPhoenix$114K
- Stephen de SouzaPhoenix$95K
- Joseph BryanPhoenix$88K
- Alan GordonPhoenix$86K
- Suhail AlamPhoenix$24K
- Rima PatelPhoenix$19K
- Matthew WelchPhoenix$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.